Skip to Content
Discovering the causes of cancer and the means of prevention

Stephanie J. Weinstein, Ph.D.

Staff Scientist

Information for Journalists

To request an interview with a DCEG investigator, contact the NCI Office of Media Relations:


Phone: 240-760-6600

Stephanie J. Weinstein, Ph.D.

Stephanie J. Weinstein, Ph.D.

Organization:National Cancer Institute
Division of Cancer Epidemiology & Genetics, Metabolic Epidemiology Branch
Address:NCI Shady Grove
Room 6E426


Dr. Stephanie Weinstein received a B.S. in biology from Tufts University and M.S. and Ph.D. degrees in nutrition from Cornell University. Her doctoral dissertation focused on one-carbon metabolism and cervical cancer. Upon completion of her graduate work, Dr. Weinstein was a postdoctoral fellow in the Nutritional Epidemiology Branch (NEB), Division of Cancer Epidemiology and Genetics, NCI, for three years. After working for one year as a nutritionist in the U.S. Department of Agriculture’s Center for Nutrition Policy and Promotion, she returned to NCI as a staff scientist in NEB in 2002, and continues her duties in the Metabolic Epidemiology Branch.

Since joining NCI, Dr. Weinstein received the NIH Fellows Award for Research Excellence and the NCI Staff Scientist/Staff Clinician Organization Travel Award.

Research Interests

Dr. Weinstein has published extensively on diet and cancer associations, with a focus on vitamin D, vitamin E, and one-carbon metabolism. In addition, she has served on the steering committee of several large collaborative/pooling projects, such as the Vitamin D Pooling Project of Rarer Cancers, the Vitamin Pooling Project of Breast and Colorectal Cancers, and the Lung Cancer Cohort Consortium.

In addition, Dr. Weinstein manages the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, a prospective cohort study that began as a clinical trial. Between 1985 and 1988, nearly 30,000 male smokers in southwestern Finland, ages 50-69, were randomized to receive daily supplementation of alpha-tocopherol (vitamin E), beta-carotene, both, or a placebo. Supplementation continued for 5–8 years, until 1993. Since that time, post-intervention follow-up of the cohort has continued, with yearly mortality and cancer incidence outcome updates. The ATBC study serves as an important resource of risk factor data and biospecimens used to study biochemical, nutritional, genetic, and molecular hypotheses relevant to cancer etiology, survival, early detection, and prevention.